PanGIA Biotech releases peer-reviewed study on diagnostics showing 97.8% sensitivity in detecting prostate cancer using urine-based liquid biopsy powered by machine learning
Delray Beach, Florida, April 2, 2026 /PRNewswire/ — PanGIA Biotech, Inc. (“PanGIA”) publishes peer-reviewed clinical research; diagnosis, “Detecting prostate cancer with a urine-based machine learning assay” 1 Demonstrates clinical validation of the PanGIA Analysis System (“PAS”) platform, a machine learning-powered urine-based liquid biopsy platform.
The study was based on PanGIA’s GH-215 clinical program and evaluated 283 participants across 26 urology facilities in the United States. results shown 97.8% sensitivity across all Gleason grades and Specificity for high-grade cancer is 97.3%the AUC was 0.91 and consistent performance was observed through cross-validation. This study was published open access. diagnosis.
This study also highlights the potential of urine-based liquid biopsy to reduce unnecessary surgical biopsies and support earlier and more informed clinical decision-making.
These findings demonstrate that prostate cancer can be detected by urine-based liquid biopsy, using machine learning to interpret patterns of biomolecular signatures derived from metabolites and other biochemical signals in urine across the disease spectrum.
This result builds on PanGIA’s previous peer-reviewed research and further positions PAS as a platform that can detect disease through pattern-based analysis, rather than relying on a single biomarker.
“This represents important external validation of our platform and strengthens the clinical and scientific foundations underlying our diagnostic pipeline,” said Holly Magliochetti, CEO and co-founder of PanGIA Biotech. “This reflects both the rigor of the study and its potential for broader application across multiple cancer types.”
PanGIA integrates non-invasive urine sample collection, biomolecular signature profiling, and machine learning analysis to enable a scalable liquid biopsy approach to early cancer detection and monitoring.
“This study reflects a different approach to cancer detection,” said Dr. Obdulio Piloto, chief scientific officer and co-founder of PanGIA Biotech. “Rather than targeting a single biomarker, this urine-based liquid biopsy uses machine learning to interpret complex biochemical patterns. This allows us to capture signals that may be missed by more reductionist approaches, supporting detection across the entire spectrum of disease.”
The full text of the study is available below.
https://www.mdpi.com/2075-4418/16/7/993
About PanGIA Biotech, Inc.
PanGIA Biotech develops AI-integrated urine and CSF-based liquid biopsy solutions designed for global scalability. PanGIA® analysis systems combine non-invasive sample collection, biomolecular feature profiling, and machine learning pattern recognition to support early detection, monitoring, and disease management, including cancer from stage 1. Backed by patents and peer-reviewed research, PanGIA is committed to driving innovations that support early detection and better health outcomes.
media contact
joy caps
Media@PanGIABiotech.com
1Hausman MS, Ambert K, Nagesetti A, Lim FBH, Swaminathan M, Cardwell RF, Piloto O. Detecting prostate cancer with a urine-based machine learning assay. diagnosis. 2026;16(7):993.
Source PanGIA Biotech
